Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Zomedica stock

Own Zomedica stock in just a few minutes.

Zomedica Corp is a drug manufacturers-specialty & generic business based in the US. Zomedica shares (ZOM) are listed on the NYSE MKT and all prices are listed in US Dollars. Zomedica employs 19 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Zomedica

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZOM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Zomedica share price

Use our graph to track the performance of ZOM stocks over time.

Zomedica shares at a glance

Information last updated 2021-04-23.
52-week range$0.06 - $2.90
50-day moving average $1.58
200-day moving average $0.90
Wall St. target price$1.20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.24

Buy Zomedica shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zomedica stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zomedica financials

Gross profit TTM $0
Return on assets TTM -29.8%
Return on equity TTM -51.94%
Profit margin 0%
Book value $0.08
Market capitalisation $819.4 million

TTM: trailing 12 months

Shorting Zomedica shares

There are currently 51.3 million Zomedica shares held short by investors – that's known as Zomedica's "short interest". This figure is 5.8% down from 54.4 million last month.

There are a few different ways that this level of interest in shorting Zomedica shares can be evaluated.

Zomedica's "short interest ratio" (SIR)

Zomedica's "short interest ratio" (SIR) is the quantity of Zomedica shares currently shorted divided by the average quantity of Zomedica shares traded daily (recently around 80.1 million). Zomedica's SIR currently stands at 0.64. In other words for every 100,000 Zomedica shares traded daily on the market, roughly 640 shares are currently held short.

However Zomedica's short interest can also be evaluated against the total number of Zomedica shares, or, against the total number of tradable Zomedica shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zomedica's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Zomedica shares in existence, roughly 50 shares are currently held short) or 0.0535% of the tradable shares (for every 100,000 tradable Zomedica shares, roughly 54 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zomedica.

Find out more about how you can short Zomedica stock.

Zomedica share dividends

We're not expecting Zomedica to pay a dividend over the next 12 months.

Zomedica share price volatility

Over the last 12 months, Zomedica's shares have ranged in value from as little as $0.063 up to $2.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Zomedica's is 0.4702. This would suggest that Zomedica's shares are less volatile than average (for this exchange).

Zomedica overview

Zomedica Corp. , a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site